Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2002 1
2010 1
2011 2
2012 3
2015 1
2018 1
2020 1
2021 3
2024 2
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Bohula EA, et al. N Engl J Med. 2026 Jan 8;394(2):117-127. doi: 10.1056/NEJMoa2514428. Epub 2025 Nov 8. N Engl J Med. 2026. PMID: 41211925 Clinical Trial.
A 3-point MACE event occurred in 336 patients (5-year Kaplan-Meier estimate, 6.2%) in the evolocumab group, as compared with 443 (8.0%) in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). A 4-point MACE event occurred in 747 p …
A 3-point MACE event occurred in 336 patients (5-year Kaplan-Meier estimate, 6.2%) in the evolocumab group, as compared with 443 (8.0%) in t …
Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.
Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernández G, Rocha JF, Holenz J, Poewe W; Epsilon Study investigators. Ferreira JJ, et al. Eur J Neurol. 2025 Jan;32(1):e16420. doi: 10.1111/ene.16420. Eur J Neurol. 2025. PMID: 39790009 Free PMC article. Clinical Trial.
The adjusted mean [95% CI] change from baseline to week 24 in MDS-UPDRS-III subscore was -6.5 [-7.9, -5.2] in the opicapone group versus -4.3 [-5.7, 3.0] in the placebo group resulting in a significant difference of -2.2 [-3.9, -0.5] favoring opicapone (p = 0.010). There w …
The adjusted mean [95% CI] change from baseline to week 24 in MDS-UPDRS-III subscore was -6.5 [-7.9, -5.2] in the opicapone group versus -4. …
Impact of veteran-led peer mentorship on posttraumatic stress disorder.
Franco Z, Ruffalo L, Curry B, Gollin-Graves M, Ahamed SI, Winstead O, Hooyer K, Pazdera M, Rein L, Lizarraga Mazaba J, Hossain MF, Stoffel V, Flower M, Madiraju P, Melka S, Berte K, Whittle J. Franco Z, et al. J Trauma Stress. 2024 Aug;37(4):617-630. doi: 10.1002/jts.23038. Epub 2024 Apr 18. J Trauma Stress. 2024. PMID: 38635149
Unadjusted survival differed by mentor military branch, p = .028, but the small mentor sample reduced interpretability. Like many community research efforts, this study lacked a control group, limiting the inferences that can be drawn. ...
Unadjusted survival differed by mentor military branch, p = .028, but the small mentor sample reduced interpretability. Like many com …
Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L, Sperling MR, Harvey JH, Sam MC, Strom LA, Blum D, Grinnell T, Cheng H. Pazdera L, et al. Epilepsia. 2018 Mar;59(3):704-714. doi: 10.1111/epi.14014. Epub 2018 Feb 16. Epilepsia. 2018. PMID: 29450890 Clinical Trial.
The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically significant (hazard ratios were 1.49 for +CBZ vs -CBZ [P = .10] and 1.27 for +VGSCi vs. -VGSCi [P = .33]). Reductions in seizure …
The higher risk of study exit in the subgroups that received CBZ (or any VGSCi) during baseline, versus other AEDs, was not statistically si …
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P. Pazdera L, et al. Cephalalgia. 2021 Sep;41(10):1075-1088. doi: 10.1177/03331024211008401. Epub 2021 May 14. Cephalalgia. 2021. PMID: 33990144 Free PMC article. Clinical Trial.
Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo for patients with documented inadequate response to 2 classes (least-squares mean difference vs placebo [95% confidence interval]: quarterly, …
Changes from baseline in monthly average migraine days during 12 weeks were significantly greater with fremanezumab compared with placebo fo …
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Marston NA, et al. JAMA. 2026 Mar 28:e263277. doi: 10.1001/jama.2026.3277. Online ahead of print. JAMA. 2026. PMID: 41903215
MAIN OUTCOMES AND MEASURES: The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). Secondary end points include …
MAIN OUTCOMES AND MEASURES: The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic …
Identification of fat-cell enhancer regions in Drosophila melanogaster.
Miller JM, Oligino T, Pazdera M, López AJ, Hoshizaki DK. Miller JM, et al. Insect Mol Biol. 2002 Feb;11(1):67-77. doi: 10.1046/j.0962-1075.2001.00310.x. Insect Mol Biol. 2002. PMID: 11841504
Development 120: 2489-2499; Hoshizaki, D.K., Lunz, R., Ghosh, M. and Johnson, W. (1995) Identification of fat-cell enhancer activity in Drosophila melanogaster using P-element enhancer traps. Genome 38: 497-506; Riechmann, V., Rehorn, K.P., Reuter, R. and Leptin, M. …
Development 120: 2489-2499; Hoshizaki, D.K., Lunz, R., Ghosh, M. and Johnson, W. (1995) Identification of fat-cell enhancer activity in Dros …
Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry.
Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR. Searls DE, et al. Arch Neurol. 2012 Mar;69(3):346-51. doi: 10.1001/archneurol.2011.2083. Epub 2011 Nov 14. Arch Neurol. 2012. PMID: 22083796
Logistic regression analysis reveals that the clinical features dysphagia (P = .004; 95% CI, 1.8-24.4), nausea or vomiting (P = .002; 95% CI, 1.6-8.2), dizziness (P = .047; 95% CI, 1.0-5.4), and Horner syndrome (P = .001; 95% CI, 2.4-26.6) were positiv …
Logistic regression analysis reveals that the clinical features dysphagia (P = .004; 95% CI, 1.8-24.4), nausea or vomiting (P …
Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E, Rocamora R, Chaves J, Moreira J, Ikedo F, Soares-da-Silva P; BIA-2093-311/EXT Investigators Study Group. Trinka E, et al. Epilepsia. 2020 Oct;61(10):2129-2141. doi: 10.1111/epi.16666. Epub 2020 Sep 17. Epilepsia. 2020. PMID: 32944934 Free PMC article. Clinical Trial.
Seizure freedom rates were 90.6% (ESL/ESL) and 80.7% (CBZ-CR/ESL; P = .0531). Responder rates remained >80% in both groups throughout the study. Incidence of serious TEAEs was similar between groups (7.3% vs 5.7%; 0% vs 1.1% possibly related), as were the incidences of …
Seizure freedom rates were 90.6% (ESL/ESL) and 80.7% (CBZ-CR/ESL; P = .0531). Responder rates remained >80% in both groups through …
20 results